Harmony Biosciences Holdings, Inc. HRMY

PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland. Poster details are listed below: Abstract Title:Phase 3, randomized, double-blind,

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece. The company is investigating EPX-100 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome in the ongoing ARGUS and LIGHTHOUSE trials, respectively. These trials are current

Harmony Biosciences Holdings, Inc. recently reported second-quarter 2026 results showing net income of US$75.43 million, up from US$39.78 million a year earlier, with basic earnings per share from continuing operations rising to US$1.30 from US$0.69. Alongside these stronger earnings, the company reported progress across its neurology pipeline and clinical trials for rare neurological diseases, which could influence how investors view the balance between its current cash-generating products...